Contributions
Abstract: PB1783
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
The principal role of autologous stem cell transplantation (AutoSCT) in patients with multiple myeloma (MM) is dependent primarilly on cytoreductive action of conditioning regimen (CR). There are different approaches to strengthen antimyeloma exposure of CR and one of them is adding a new drug to standard used melphalan
Aims
The aim was to compare the effectiveness of standard used CR with melphalan (Mel) monotherapy with combination of Mel with thiotepa (Mel/Thio) and combination of Mel with carfilzomib (Mel/Carfil). Progression free survavl (PFS) was chosen as a measure of CR effectiveness
Methods
Response to therapy before AutoSCT was identified with IWG criteria. PFS was calculared from the data of AutoSCT in patients without MM progression during the first 3 months. Thre groups of patients were formed: the first group of 27 patients with CR Mel200/140, the second group of 9 patients with CR Mel/Thio and the third one of 8 patients with CR Mel/Carfil
Results
Median age of patients in the group one, two and three was 54y, 59y and 57.5 y accordingly. The number of patients with comple, very good partial and partial response was 10, 7 and 10 in the first group, 1, 4 and 1 in the second group and 1, 1 and 6 in the third group. The patients' follow-up period was 14 (3-40), 13 (10-26) and 11.5 (3-18) months in the groups accordingly. The median PFS was 40 mo, 13 mo and not achived in the groups accordingly: p=0.833. Difference in the data of PFS between indidvidual groups has not been found too
Conclusion
Despite the lack of distinction, the trend towards improved PFS in the group with the pre-eminent number of MM patients with partial response treated with regimen Mel/Carfil possibly reflects a more pronounced antimyeloma effect of this CR. A longer period of observation is needed for the final conclusion
Keyword(s):
Abstract: PB1783
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
The principal role of autologous stem cell transplantation (AutoSCT) in patients with multiple myeloma (MM) is dependent primarilly on cytoreductive action of conditioning regimen (CR). There are different approaches to strengthen antimyeloma exposure of CR and one of them is adding a new drug to standard used melphalan
Aims
The aim was to compare the effectiveness of standard used CR with melphalan (Mel) monotherapy with combination of Mel with thiotepa (Mel/Thio) and combination of Mel with carfilzomib (Mel/Carfil). Progression free survavl (PFS) was chosen as a measure of CR effectiveness
Methods
Response to therapy before AutoSCT was identified with IWG criteria. PFS was calculared from the data of AutoSCT in patients without MM progression during the first 3 months. Thre groups of patients were formed: the first group of 27 patients with CR Mel200/140, the second group of 9 patients with CR Mel/Thio and the third one of 8 patients with CR Mel/Carfil
Results
Median age of patients in the group one, two and three was 54y, 59y and 57.5 y accordingly. The number of patients with comple, very good partial and partial response was 10, 7 and 10 in the first group, 1, 4 and 1 in the second group and 1, 1 and 6 in the third group. The patients' follow-up period was 14 (3-40), 13 (10-26) and 11.5 (3-18) months in the groups accordingly. The median PFS was 40 mo, 13 mo and not achived in the groups accordingly: p=0.833. Difference in the data of PFS between indidvidual groups has not been found too
Conclusion
Despite the lack of distinction, the trend towards improved PFS in the group with the pre-eminent number of MM patients with partial response treated with regimen Mel/Carfil possibly reflects a more pronounced antimyeloma effect of this CR. A longer period of observation is needed for the final conclusion
Keyword(s):